Primary Prevention of Hypertension in Obese Adolescents
The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are:
- Test the hypothesis that lowering uric acid will improve endothelial function.
- Test the hypothesis that lowering uric acid will reduce plasma renin activity and serum angiotensin II levels.
- Test the hypothesis that lowering uric acid will reduce markers of inflammation
|Obesity Pre-Hypertension Hyperuricemia||Drug: Allopurinol vs. Probenecid vs. Placebo||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Systemic Vascular Resistance (measured by bioimpedance)
- Brachial Artery Reactivity
- Serum Angiotensin 2
- Serum MCP-1
- Ambulatory BP
- Casual BP
- thromboxane B2
- leptin adiponectin
|Study Start Date:||February 2006|
The trial will be a double blinded, placebo control trial of two uric acid lowering agents. The endpoints for this trial will be, endothelial function, systemic vascular resistance, plasma renin activity, MCP-1 and CRP. Upon recruitment and informed consent, children will undergo initial screening. This will include medical history, family history, dietary history, review of systems (questionnaire used and validated in pediatric hypertension clinic) and pediatric quality of life questionnaire. They will have a physical exam, casual and ambulatory blood pressure monitoring (see below) and screening laboratory analysis that will include CBC, electrolytes, BUN, Cr, Uric acid, AST, ALT and urinary micro-albumin to creatinine ratio. Children with serum uric acid less than 5.0mg per dl will be enrolled as controls and only have baseline studies at Screening and Visit 1. Children with serum uric acid equal to or greater than 5.0mg per dl will be randomized (in a one to one to one ratio) to receive placebo, allopurinol or probenecid.
Study drug (or placebo) will be administered for 2 months. During the first week, subjects will take one tablet (placebo, 150mg allopurinol or 250mg probenecid) twice daily. At the end of one week subjects will be instructed to increase to 2 tablets (placebo, 300mg allopurinol or 500mg probenecid) twice daily. Data collection will occur during screening, after one and two months on the study drug and one month after completion of the study drug.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00288158
|United States, Texas|
|Texas Children's Hospital|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Daniel I Feig, MD, PhD||Baylor College of Medicine|